SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : dsco Discovery Laboratories -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (182)11/7/2008 7:28:07 PM
From: Arthur Radley  Respond to of 318
 
I now firmly believe that the management of this company doesn't have a clue. As with you.........why in the heck did the CEO even bring up the potential for the quick review process...knowing the backlog at the FDA. The bad news is the stock dropped like a rock in A-H trading, however, the volume was light. If I can get a decent reentry price on Monday I might buy back...however, now I'm thankful that I bailed when I did.



To: rkrw who wrote (182)11/7/2008 7:29:26 PM
From: fred hayes1 Recommendation  Read Replies (1) | Respond to of 318
 
Jim, you are right, of course. DSCO should not have publicly anticipated the 60 day review and I'm sure they are responsible for some share of the delays. But my guess is that the FDA coulda/shoulda treated this drug with a little more urgency. The whole episode is pretty sorry...

fred


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News